SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    ________

                                    FORM 6-K
                               Amendment Number 1

                        REPORT OF FOREIGN PRIVATE ISSUER
                      PURSUANT TO RULE 13A-16 OR 15D-16 OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                        For the month of November, 2002

                                  Serono S.A.
                    ----------------------------------------
                               (Registrant's Name)

                            15 bis, Chemin des Mines
                                Case Postale 54
                                CH-1211 Geneva 20
                                  Switzerland
                    ----------------------------------------
                    (Address of Principal Executive Offices)

                                    1-15096
                    ----------------------------------------
                              (Commission File No.)

     (Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.)

     Form 20-F    X       Form 40-F
               ------               -------

     (Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101 (b)(1).)
                                                       -------

     (Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101 (b)(7).)
                                                       -------

     (Indicate by check mark whether the registrant by furnishing the
information contained in this form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)

     Yes        No   X
         -----     ------

     (If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-      )
                                                 ------



GENSET                                                                    SERONO


Media Release



FOR  IMMEDIATE  RELEASE
-----------------------


                         RESULTS OF SERONO TENDER OFFER
                         -SERONO HOLDS 91.8% OF GENSET-


GENEVA,  SWITZERLAND  AND PARIS, FRANCE, NOVEMBER 8, 2002 - Serono S.A. (Virt-x:
SEO,  NYSE: SRA) and Genset S.A. (Euroclear: 5433) announced that, following its
subsequent  offering period, Serono holds 91.8% of the capital and voting rights
of Genset, which successfully concludes the tender offer for Genset by Serono.

In a press release issued this morning, the Conseil des Marches Financiers (CMF)
indicated that Serono France Holding S.A. holds:
     -    7,557,702 Genset shares, representing 91.8% of the 8,232,350 shares
          outstanding;
     -    515,931 Genset bonds convertible or exchangeable into new or existing
          shares (OCEANEs), representing 98.8% of the 522,223 OCEANEs
          outstanding;
     -    all the warrants outstanding.

Serono France Holding S.A. will continue to buy Genset shares on the Nouveau
Marche at a price of 9.75 euros and will inform the market upon suspension of
these purchases.


                                       ***


These  materials  contain certain statements that are neither reported financial
results  nor  other  historical  information.  Because  these  forward-looking
statements  are  subject  to  risks and uncertainties, actual future results may
differ  materially from those expressed in or implied by the statements. Many of
these  risks  and uncertainties relate to factors that are beyond the companies'
ability  to  control  or  estimate  precisely, such as future market conditions,
currency fluctuations, the behavior of other market participants, the actions of
governmental regulators and other risk factors detailed in Serono's and Genset's
filings with the SEC. Readers are cautioned not to place undue reliance on these
forward-looking  statements,  which  speak only as of the date of this document.
The  companies do not undertake any obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the
date  of  these  materials.


                                     -more-


ABOUT SERONO
Serono  is  a  global  biotechnology  leader.  The  Company  has six recombinant
products  on  the  market,  Gonal-F(R),  Luveris(R),  Ovidrel(R)/Ovitrelle(R),
Rebif(R),  Serostim(R) and Saizen(R) (Luveris(R) is not approved in the USA). In
addition  to  being  the  world leader in reproductive health, Serono has strong
market  positions  in  neurology,  metabolism and growth. The Company's research
programs  are  focused  on  growing  these  businesses  and  on establishing new
therapeutic areas. Currently, there are seventeen new molecules in development.

In 2001, Serono achieved worldwide revenues of US$1.38 billion, and a net income
of  US$317  million,  making  it  the third largest biotech company in the world
based  on  revenues.  The Company operates in 45 countries, and its products are
sold  in  over 100 countries. Bearer shares of Serono S.A., the holding company,
are  traded on the virt-x (SEO) and its American Depositary Shares are traded on
the  New  York  Stock  Exchange  (SRA).


ABOUT  GENSET
Genset  is  a  genomics-based  biotechnology  company  focused  on  generating a
pipeline  of  drug targets and drug candidates in the areas of CNS and metabolic
disorders.  Genset  has successfully used its integrated technology platform and
association  studies approach to identify and characterize drug targets and drug
response  markers  in  the fields of CNS, metabolic and other diseases. Building
upon the expertise accumulated in various alliances with pharmaceutical partners
and  its portfolio of genomic patents, Genset discovers and validates novel drug
targets  and  candidates  for its own account. Its teams have already discovered
and  launched  the  development  of a lead protein in the metabolism field named
Famoxin,  and  are  continuing  their  research  with  a view to discovering and
developing  other  drugs.  Genset's news releases are available on the Company's
Web  site  at  http://www.genset.fr.
               ---------------------


FOR MORE INFORMATION, PLEASE CONTACT:


SERONO IN GENEVA, SWITZERLAND:
MEDIA RELATIONS:            INVESTOR RELATIONS:         IMAGE SEPT FRANCE :
Tel: +41-22-739 36 00       Tel: +41-22-739 36 01       Tel : + 33 1 53 70 74 68
Fax: +41-22-739 30 85       Fax: +41-22-739 30 22       Fax : + 33 1 53 70 74 80
http://www.serono.com       Reuters: SEOZ.VX / SRA.N
---------------------       Bloomberg: SEO VX / SRA US

SERONO, INC., ROCKLAND, MA
MEDIA RELATIONS:
Tel.  +1 781 681 2340
Fax:  +1 781 681 2935
http://www.seronousa.com
------------------------



GENSET                      BURNS MCCLELLAN
+331 55 04 59 00            +1 212 213 0006
Marc Vasseur                Media:  Justin Jackson
Chairman & CEO              Investors:  Jonathan M. Nugent


           GENSET is listed on the NOUVEAU MARCHE of the Paris Bourse
             Euroclear: 5433 - - Bloomberg: GNST FP - Reuters: GEN.F


                                      -end-



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                    SERONO S.A.
                                    a Swiss corporation
                                    (Registrant)



November 8, 2002                    By:    /s/ Jacques Theurillat
                                           ------------------------------
                                    Name:  Jacques Theurillat
                                    Title: Deputy Chief Executive Officer